Clinical Trial Update: 10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

View source ↗

Summary

This completed clinical trial evaluates 10-year coronary heart disease risk and treatment patterns in postmenopausal women with early breast cancer who are rece…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Coronary Artery Disease

Drugs mentioned

• ARIMIDEX (anastrozole)
• Aromasin (exemestane)
• FEMARA (letrozole)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Status: COMPLETED